Kornimate/medical-research-clean huggingface dataset:
plexin d1 as a potential biomarker inpm/dm

Conditions: Polymyositis; Dermatomyositis

Summary: evaluation of level of serum circulating plexin d1 on extacellular vesicles in adult pm/dm patients and juvenile dermatomysitis.

polymyositis (pm) and dermatomyositis (dm) are autoimmune inflammatory diseases that primarily target muscle. autoimmune dermatomyositis (dm) is a rare inflammatory disease that mainly affects skin, muscle, and lung. inflammatory myopathies (ims) often have distinct histopathologic features suggesting humorally mediated involvement of the microcirculation in dermatomyositis (dm), including early capillary deposition of the complement c5b-9 membranolytic attack complex (mac) and secondary ischaemic changes; and cd8 t-cell-mediated and mhc1-restricted autoimmune attack of myofibers in polymyositis (pm) and inclusion body myositis. plexins are a conserved family of large proteins (\~200kda) that are the canonical receptors for semaphorin molecules. plexins are divided into four classes, a through d. recently, plexin and semaphorin molecules have been shown to control cell movement and cell-cell interaction in the immune system . extracellular vesicles (evs) are lipid bilayer membrane vesicles that exist in various bodily fluids. evs are released by normal, diseased, and transformed cells in vitro and in vivo and are capable of carrying lipids, proteins, mrnas, non-coding rnas, and even dna. they are abundant in serum and plasma and have been a source of considerable interest as potential disease biomarkers. normally, they maintain physiological functions by transferring biological information to neighboring cells and facilitating intercellular communication, but are also involved in the pathogenesis of numerous autoimmune diseases lc/ms analysis identified 1220 proteins in serum evs. of these, plexin d1 was enriched in those from pm/dm patients.

Eligibility criteria:
inclusion criteria: 1. adult pm/dm patients . 2. juvenile dermatomyositis patients. exclusion criteria: * 1-patients with other autoimmune diseases ( rheumatoid arthritis ,systemic lupus erythematosus, polyarteritis nodosa sarcoidosis, scleroderma, spondylarthritis and inflammatory bowel disease) 2-patients with malignant tumors 3-patients with active infection 4-patients with severe heart, lung, and kidney dysfunction
email reminder to follow up with primary physician

Conditions: Act Code - Emergency

Summary: the purpose of this study is to see if patients who receive an email reinforcing their discharge instructions after being discharged from the emergency department will have an affect on follow-up care with their primary physician.

when a patient is treated in the emergency department (ed), they experience a whirlwind of care involving multiple diagnostics and treatments. they are often discharged home with instructions to follow up with their primary care physician. this follow up care is crucial to ensuring optimal patient outcomes and re-establishing continuity of care. despite efforts to communicate clearly and effectively, ed patients often have difficulty understanding their follow-up care instructions. several different methods have been employed to attempt to improve the follow-up rates after emergency department care, including providing patients with an easily read, printed copy of discharge instructions, having a nurse or mid-level provider call patients days after discharge from the ed to ensure that they understood discharge instructions. one medium for communication that has become increasingly relevant in recent years is electronic mail (email). because of its pervasiveness and relative ease of use, email offers a potentially valuable resource for augmenting and improving communication between physicians and patients. this study will assess whether an email reminder with follow up instructions one day after ed visit occurs will increase follow up rates and timely follow up rates.

Eligibility criteria:
inclusion criteria: * 1. patients triaged to category 2, 3, and 4 and placed in a room for care at st. joseph mercy hospital-ann arbor emergency department 2. primarily english speaking. 3. \>18 years of age 4. have a primary physician who is part of integrated health associates 5. have access to an email account exclusion criteria: * 1. patients triaged to category 1 or 5 placed in a room at stl joseph mercy hospital-ann arbor (category 1 patients are not typically discharged home from the hospital. category 5 patients could potentially be interfered with if attempting implementation of the communication instrument. category 5 patients are typically very straightforward visits with minimal requirement for follow-up appointments) 2. patients \< age 18 3. prisoners or institutionalized persons 4. patients with a mental-health related chief complaint 5. not primarily english speaking (the potential language barriers could interfere with ability to communicate via email which will be written in english) 6. under temporary or permanent custodianship (used as a surrogate for ongoing lack of mental competence or consciousness) 7. prior participation in this study. (a patient may only participate once).
effect of biomechanical correction in medial tibiofemoral joint osteoarthritis

Conditions: Osteoarthritis Knee

Summary: effect of biomechanical correction of tibia on medial joint space loading, varus deformity and functional tasks in patients with medial tibiofemoral joint osteoarthritis in which participants will be taken. the outcome measures taken are trauma cad software, nprs, womac and goniometery will be measured at the baseline after 3rd week of the intervention.

background: knee osteoarthritis (koa) are very prevalent chronic disease of the joint which causing the functional disability and pain specifically in older adults. objective: purpose of the study is to see that the biomechanical correction on the tibia and varus deformity is effective in the conventional treatment of participants with the koa. study design: a randomized single group pretest-post test clinical trial. methodology: total '5' subjects were included in the study with the age of 40 to 60 years based on exclusion and inclusion criteria. for the pain, the nprs will be taken, goniometer taken for the measurement of range of motion, womac will be taken for the physical activity measurement and cad software will be taken to see the alignment of the affected limb. conventional treatment will also be given. conclusion: biomechanical correction shows the significant improvement and improves the subject's physical activity and reduces the pain and stiffness. keywords: obesity, osteoarthritis, pain and physical therapy modalities

Eligibility criteria:
inclusion criteria: • 40-60 years of age paients will be included in this study * bmi (25.1±4.2) kg/m2 * subjects with stiffness and knee pain * subjects with objection of pain in knee joint that was aggravated by performing 2 or more of the following functional activities: prolonged cross sitting, stair assents and descent, squatting and kneeling. * subjects who are willing to take participation * individuals who obeys the commands properly * individuals exhibiting the subsequent biomechanical changes on screening * q angle \>12 degree for male and \>15 degree for female, femoral anteversion, external tibial torsion \>15 degree, lack of ≥ 5 degree of knee extension in supine position. exclusion criteria: * • knee meniscal injuries or ligament injuries * lately history of lower limb trauma and surgery * in recent times fracture in lower extremity * in lower extremity metal plantation * cardio vascular conditions * patella dislocation/subluxation * abnormality in foot or deformity

Keywords: obesity osteoarthritis physical therapy modalities
electron beam intraoperative radiation therapy following chemoradiation in patients with pancreatic cancer with vascular involvement

Conditions: Pancreas Cancer

Summary: this research study is studying an intervention as a possible treatment for pancreatic cancer.

in this research study, the investigators are researching how well iort during surgery works in treating pancreatic cancer after 3-6 months of chemotherapy and external radiation therapy. iort works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy. the investigators believe that the administration of iort after 3-6 months of chemotherapy will help to stop the cancer cells from growing. the fda (the u.s. food and drug administration) has not approved iort for this specific disease but it has been approved for other uses.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * ecog performance status 0-1 * previous completion of at least three (3) months of either gemcitabine plus nab-paclitaxel or folfirinox (5-fluorouracil, oxaliplatin, irinotecan and leucovorin) * previous completion of either stereotactic-body radiation therapy (sbrt) (minimum 24 gy) or external beam irradiation (ebrt) (minimum 45 gy) * participation in any investigational drug study within 4 weeks preceding the start of study treatment is permitted. * women of childbearing potential (wocbp) must use appropriate method(s) of contraception. wocbp should use an adequate method to avoid pregnancy for 5 months after iort. * men who are sexually active with wocbp must use any contraceptive method with a failure rate of less than 1% per year. men receiving nivolumab and who are sexually active with wocbp will be instructed to adhere to contraception for a period of 7 months after iort. women who are not of childbearing potential, i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception. * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * evidence of disease progression or distant metastases. * pregnant or lactating women * treatment for other invasive carcinomas within the last five years who are at greater than 5% risk of recurrence at time of eligibility screening. carcinoma in-situ and basal cell carcinoma/ squamous cell carcinoma of the skin are allowed. * major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * an active infection requiring systemic therapy * other serious medical conditions that the investigator feels might compromise study participation

Keywords: pancreatic cancer
susceptibility of motor-evoked potentials to varying targeted blood levels of dexmedetomidine

Conditions: Scoliosis

Summary: reduction of the spinal cord injuries during scoliosis surgery is a major goal of the anesthesia and surgical team. despite improvement in scoliosis surgery over the years, the development of neurological deficits remains the most feared complication of spine surgery. during scoliosis surgery it is very important to monitor the spinal cord to detect spinal cord injury with surgical manipulation. continuous or intermittent intraoperative electrophysiological monitoring (neuron-monitoring) is used routinely during these procedures to provide the surgeon with information concerning the integrity of neurological structures at risk. all neuron-monitoring modalities are affected by the anesthetic regimen used. of the various intravenous anesthetic drugs, the combination of propofol, remifentanil and dexmedetomidine appear to impact neuron-monitoring the least. the current anesthetic practice is to use the three drugs in combination at doses that do not depress the signals but there is no data relating targeted dexmedetomidine and propofol blood levels to neuron-monitoring signals. the lack of data results in wide variability in dosing with consequent variability in patient response. hypothesis: clinically relevant blood levels of dexmedetomidine will affect the amplitude of transcranial motor-evoked potentials (tcmep) either independently or by interaction with propofol in a dose dependent manner.


Eligibility criteria:
inclusion criteria: * subjects must be 10 to 25 years of age * diagnosis of idiopathic scoliosis is established * subject's legal authorized representative has given written, informed consent to participate in the study and, where appropriate, the subject has given assent to participate * american society of anesthesiology physical status one/two * patients scheduled for posterior spinal fusion only exclusion criteria: * • patients with neuromuscular scoliosis and patients with motor or sensory deficit in the lower extremities * patients with allergy to, or contraindication for the drugs or techniques used in the study * morbid obesity (body mass index higher than 40) * history of malignant hyperthermia * patient with severe cardiopulmonary disease (pulmonary hypertension, cardiomyopathy, mechanical ventilation)

Keywords: dexmedetomidine neuromonitoring spine procedures safe dose 1- safe dose of dexmedetomidine when used in total intravenous anesthesia for procedures require neuromonitoring 2- safe dose of propofol when uses in comination with dexmedetomidine in neuromontoring 3effect of dexmedetomidine on somatosensory evoked potential and motor evoked potentials
long-term monitoring of sleep with ear-eeg in patients with chronic pain

Conditions: Chronic Pain; Insomnia

Summary: insomnia is reported by more than 50% of patients with chronic pain. in this study, the investigators aim to advance the understanding of physiological sleep in individuals with chronic pain. to do this the investigators will monitor at-home sleep with an ear-eeg over 20 nights in patients with chronic pain and collect self-reported measures of sleep and pain. the collected data will be used to explore and characterize intra-individual variations in sleep metrics (e.g. total sleep time, time in each sleep stage (n1, n2, n3, rem), sleep latency, rem stage latency, wake after sleep onset, sleep efficiency, number of arousals and arousal index) over 20 nights.


Eligibility criteria:
inclusion criteria: for a subject to be eligible, all inclusion criteria must be answered "yes": * understand and write danish. * pain present on most days or every day during the past 3 months. * pain limits daily activities or work on some days, most days or every day during the past 3 months. * pain intensity equal to or larger than 4 on 0-10 numeric rating scale \[nrs\] within the last week. * informed consent obtained before any study related activities. exclusion criteria: for a subject to be eligible, all exclusion criteria must be answered "no": * previous stroke or cerebral haemorrhage and any other structural cerebral disease. * obstructive sleep apnoea (defined as yes to 3 or more questions in the stop-bang questionnaire for women and 4 or more questions for men). * teeth grinding (bruxism). * pregnancy or lactation (pregnancy is screened for through self-reporting as no risks regarding pregnancy have been identified for the described study procedures). * narrow or malformed ear canals or piercings, making ear-eeg infeasible. * allergic contact dermatitis caused by metals or generally prone to skin irritation. * people judged incapable, by the investigator, of understanding the participant instruction or who are not capable of carrying through the investigation.
respiratory and physical outcomes in different types of office workers

Conditions: Work-related Illness

Summary: there are no studies in the literature reporting the posture, chest mobility, dyspnea, flexibility, quality of life and physical activity levels of emergency call center employees. the aims of this observational study are; 1) to evaluate posture, chest mobility, strength, dyspnea, flexibility, musculoskeletal disorders, physical activity and quality of life in emergency call center workers and office workers, 2) to reveal the relationships between these parameters of both research groups and 3) the aim is to compare these measurement parameters in emergency call center workers and office workers.

over time, there has been an increase in the number of office workers and the use of computers. working in a static position for long working hours and improper working postures can lead to loss of flexibility in the muscles, decrease in thoracic mobility, pain in the musculoskeletal system and deterioration of ideal posture. emergency call center employees work long hours, in shifts that require serious attention, where stress is intense and the circadian rhythm is disrupted. there is no study in the literature that evaluates the posture, chest mobility, dyspnea, flexibility and physical activity levels of emergency call center employees. therefore, the aim of our study is; it is a comparative evaluation of posture, chest mobility, cough strength, dyspnea flexibility, musculoskeletal disorders, physical activity level and quality of life in emergency call center operators and desk workers.

Eligibility criteria:
inclusion criteria for emergency call center workers * being an operator at izmir 112 emergency call center * being 18 years or older * volunteering to participate in the study * being able to understand and answer surveys inclusion criteria for office workers * being actively working at a desk * being 18 years or older * volunteering to participate in the study * being able to understand and answer surveys exclusion criteria: * have any history of acute/chronic infection, physical or mental disability/disease and/or cognitive impairment that would prevent measurement. * being pregnant * being able to exercise regularly

Keywords: office workers call center operators musculoskeletal discomfort dyspnea posture thoracic mobility
oblimersen in treating patients with merkel cell carcinoma

Conditions: Recurrent Neuroendocrine Carcinoma of the Skin; Stage I Neuroendocrine Carcinoma of the Skin; Stage II Neuroendocrine Carcinoma of the Skin; Stage III Neuroendocrine Carcinoma of the Skin; Stage IV Neuroendocrine Carcinoma of the Skin

Summary: this phase ii trial is studying how well oblimersen works in treating patients with merkel cell cancer. biological therapies, such as oblimersen, may interfere with the growth of tumor cells and slow the growth of merkel cell carcinoma (skin cancer).

primary objectives: i. determine the overall response rate in patients with merkel cell carcinoma treated with oblimersen. secondary objectives: i. determine the time to progression in patients treated with this drug. ii. determine the response duration in patients treated with this drug. iii. determine the safety and tolerability of this drug in these patients. iv. determine the pharmacodynamic effects of this drug on bcl-2 expression and apoptosis in tumor biopsy specimens from these patients. outline: this is an open-label, multicenter study. patients receive oblimersen iv continuously on days 1-14. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed merkel cell carcinoma * metastatic or regionally recurrent disease * localized disease not amenable to curative therapy (surgery or radiotherapy) also allowed * measurable disease * at least 20 mm by conventional techniques or at least 10 mm by spiral ct scan * no known brain metastases * previously resected or irradiated brain metastases allowed if stable for at least the past 3 months and no evidence of neurological compromise exists * performance status - karnofsky 60-100% * absolute neutrophil count \>= 1,500/mm\^3 * platelet count \>= 100,000/mm\^3 * wbc \>= 3,000/mm\^3 * ast/alt =\< 2.5 times upper limit of normal * bilirubin normal * inr =\< 1.5 * creatinine normal * creatinine clearance \>= 60 ml/min * no atrial fibrillation unless stable for at least the past 6 months * no symptomatic congestive heart failure * no unstable angina pectoris * no cardiac arrhythmia * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * adequate venous access * no peripheral neuropathy \> grade 1 * no active or ongoing infection * no other concurrent uncontrolled illness * no prior grade 3 or 4 anaphylactic reaction to phosphorothioate oligonucleotide * no psychiatric illness or social situation that would preclude study compliance * more than 3 weeks since prior chemotherapy and recovered * more than 3 weeks since prior radiotherapy and recovered * no prior radiotherapy to 25% or more of bone marrow * more than 3 weeks since prior investigational therapy and recovered * no prior oblimersen * no other concurrent investigational agents * no concurrent anticoagulation except 1 mg of warfarin for mediport patency * no concurrent combination antiretroviral therapy for hiv-positive patients
senescence in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: the study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (msc) functionality in patients with chronic kidney disease (ckd).

the proposed studies will examine cellular senescence and the effect of senolytic therapy on senescent cell burden, frailty, and adipose-derived mesenchymal stem cell function in individuals with diabetic chronic kidney disease.

Eligibility criteria:
inclusion criteria: 1. age 40-80 years 2. chronic kidney disease estimated glomerular filtration rate (egfr) 15-45 ml/min/1.73m2 3. diabetes mellitus and taking diabetes medications exclusion criteria: 1. concomitant glomerulonephritis, 2. nephrotic syndrome, 3. solid organ transplantation, 4. autosomal dominant or recessive polycystic kidney disease, 5. known renovascular disease, 6. pregnancy, 7. active immunosuppression therapy, 8. hemoglobin a1c≥10% at screening, 9. history of active substance abuse (including alcohol) within the past 2 years, 10. current alcohol abuse (\>3 alcoholic beverages/day or \>21 per week), 11. body weight \>150 kg or body mass index\>50 12. human immunodeficiency virus infection 13. active hepatitis b or c infection 14. tyrosine kinase inhibitor therapy 15. known hypersensitivity or allergy to dasatinib or quercetin 16. inability to give informed consent 17. uncontrolled systemic lupus erythematosus 18. uncontrolled pleural/pericardial effusions or ascites 19. new invasive cancer except non-melanoma skin cancers 20. invasive fungal or viral infection 21. inability to tolerate oral medications 22. total bilirubin\>2x upper limit of normal 23. subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for cyp3a4, cyp2c8, cyp2c9, or cyp2d6 or strong inhibitors or inducers of cyp3a4 (e.g. cyclosporine, tacrolimus or sirolimus). if antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic. 24. subjects on strong inhibitors of cyp3a4. 25. subjects on therapeutic doses of anticoagulants (warfarin (coumadin);rivaroxaban (xarleto); apixaban (eliquis); dabigatran (pradaxa, prazaxa) or other). 26. subjects on antiplatelet agents ((clopidogrel (plavix); dipyridamole + asprin (aggrenox); ticagrelor (brilinta); prasugrel (effient); ticlopidine (ticlid) or other) who are unable or unwilling to reduce or hold therapy prior to and during the 3-day drug dosing. subjects may continue their previous regimen on day 4. 27. subjects on quinolone antibiotic therapy for treatment or for prevention of infections within 10 days 28. subjects taking h2-antagonists or proton pump inhibitors and unwilling to discontinue therapy 1 week prior and 2 weeks following enrollment. 29. corrected qt interval (qtc)\>450 msec 30. presence of any condition that the investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial.